drugset / Trial / NCT05481736

Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study

NCT05481736 ↗

Phase 2 Completed 32 enrolled COMPASS Pathways
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Efficacy and Safety of COMP360 Psilocybin therapy in Anorexia Nervosa: a Proof-of-concept Study

Timeline

Start
2022-10-12
Primary completion
2024-11-18
Completion
2024-11-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Psilocybin Other / unclassified 1 mg —
Subject Psilocybin Other / unclassified 25 mg —

Indications